OPRX Stock - OptimizeRx Corporation
Unlock GoAI Insights for OPRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $92.13M | $71.52M | $62.45M | $61.29M | $43.31M |
| Gross Profit | $59.38M | $42.90M | $38.97M | $35.64M | $24.11M |
| Gross Margin | 64.5% | 60.0% | 62.4% | 58.1% | 55.7% |
| Operating Income | $-13,706,000 | $-26,402,000 | $-12,290,738 | $361,100 | $-2,135,319 |
| Net Income | $-20,110,000 | $-17,566,000 | $-11,438,440 | $378,079 | $-2,207,127 |
| Net Margin | -21.8% | -24.6% | -18.3% | 0.6% | -5.1% |
| EPS | $-1.10 | $-1.03 | $-0.64 | $0.02 | $-0.15 |
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 8th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $6← $7 |
| December 20th 2024 | Stephens | Initiation | Equal Weight | $5.5 |
| July 25th 2024 | B. Riley Securities | Resumed | Buy | $18.5 |
| April 4th 2024 | JMP Securities | Initiation | Mkt Outperform | $15 |
| January 3rd 2024 | Barclays | Initiation | Equal Weight | $15 |
| February 2nd 2023 | B. Riley Securities | Resumed | Buy | $30 |
| November 1st 2022 | Stifel | Initiation | Buy | $19 |
| July 15th 2022 | SVB Leerink | Initiation | Outperform | $38 |
Earnings History & Surprises
OPRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $0.23 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.03 | $0.20 | +566.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.03 | $0.24 | +700.0% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.11 | $0.08 | +172.7% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $0.25 | $0.30 | +20.0% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $0.06 | $0.12 | +100.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.07 | $0.02 | +128.6% | ✓ BEAT |
Q2 2024 | Apr 16, 2024 | $-0.13 | $0.26 | +300.0% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $0.32 | $0.26 | -18.8% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $0.03 | $0.09 | +260.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.01 | $-0.01 | -53.4% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $0.24 | $0.25 | +4.2% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.04 | $0.07 | +90.7% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $0.10 | $0.04 | -60.0% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.01 | $-0.01 | -15.2% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $0.18 | $0.22 | +22.2% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $0.13 | $0.09 | -30.8% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $0.07 | $0.10 | +42.9% | ✓ BEAT |
Latest News
OptimizeRx Announced Four New Partner Agreements That Expand Its In-Workflow Point-of-care Network, Fortify Its Long-term Competitive Position, And Increase Total National Provider Identifier Reach, Deal Terms Were Undisclosed
📈 PositiveStephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $17
➖ NeutralCitizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $24
📈 PositiveOptimizeRx Sees FY2026 Sales $118.000M-$124.000M vs $118.125M Est
📈 PositiveOptimizeRx Raises FY2025 Sales Guidance from $104.000M-$108.000M to $105.000M-$109.000M vs $106.506M Est
📈 PositiveOptimizeRx Q3 Adj. EPS $0.20 Beats $0.04 Estimate, Sales $26.067M Beat $23.833M Estimate
📈 PositiveJMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23
📈 PositiveOptimizeRx Partners With Lamar Advertising To Revolutionize OOH Advertising For Pharmaceutical And Healthcare Brands
📈 PositiveOptimizeRx Appoints Brendan Merrell As COO
➖ NeutralOptimizeRx Non-GAAP EPS of $0.08 beats by $0.20, revenue of $21.9M beats by $3.21M
📈 PositiveFrequently Asked Questions about OPRX
What is OPRX's current stock price?
What is the analyst price target for OPRX?
What sector is OptimizeRx Corporation in?
What is OPRX's market cap?
Does OPRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OPRX for comparison